Journal of Clinical Oncology
Articles in this Issue
A phase 1b study of tegavivint, a TBL1 inhibitor, with gemcitabine in patients with relapsed or refractory osteosarcoma (TIGER).
TPS11586 Background: The Wnt-signaling pathway and its downstream transcriptional effector, β-catenin, are dysregulated in...
A phase II, single-arm trial of adebrelimab plus nab-paclitaxel and carboplatin as first-line therapy for advanced thymic carcinoma: Interim efficacy and safety results.
e20171 Background: Thymic carcinoma (TC) is a rare and aggressive malignancy with poor prognosis in advanced stages. Given...
Real-world characterization of SEZ6, a transmembrane protein expressed in various solid tumors.
3082 Background: Seizure-related homolog 6 (SEZ6) is a transmembrane protein involved in neuronal development that is down...
Travel time to cancer care as it relates to care access, transportation distress, and financial toxicity: Findings from the Cancer Experience Registry.
1537 Background: Longer travel time to cancer care has been linked to worse prognosis and quality of life for patients. Th...
Post–PD-1 failure in advanced melanoma: Real-world outcomes with lenvatinib-based versus non-lenvatinib-based therapy.
e21520 Background: Post–anti–PD-1 advanced melanoma has few effective salvage options and CHEMO outcomes are modest. We ev...
Reassessing obesity and smoking as renal cell carcinoma risk factors: TriNetX 2016-2025 analysis.
e16527 Background: Obesity and smoking are established risk factors for renal cell carcinoma (RCC). Most prior studies pre...
Adult medulloblastoma: Long-term follow-up analysis of a single-center cohort.
e14104 Background: Medulloblastoma (MB) is a malignant embryonal neoplasm of the central nervous system (CNS) that is more...
Faith in the balance: Examining religious and spiritual influences on cancer treatment decisions.
e23268 Background: Religion and spirituality are fundamental aspects of many individuals’ lives, providing guidance, comfo...
AI-driven multi-scale histopathologic classification of epithelial ovarian cancer to support precision oncology.
5608 Background: Epithelial ovarian cancer (EOC) comprises five histologically distinct subtypes associated with divergent...
Phase II study of adjuvant anlotinib for esophageal squamous cell carcinoma with residual disease following neoadjuvant therapy.
e16138 Background: Patients with esophageal squamous cell carcinoma (ESCC) who fail to achieve a pathological complete res...
Artificial intelligence–integrated profiling of JAK-STAT, MAPK, and RTK–RAS signaling alterations in chemotherapy-treated early-onset colorectal cancer among disproportionately affected populations.
e15510 Background: Early-onset colorectal cancer (EOCRC; < 50 years) is increasing rapidly, with disproportionate burde...
Prognostic impact of circulating tumor DNA in pancreatic ductal adenocarcinoma: A meta-analysis.
e16430 Background: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy and the third leading cause of canc...
Defining safe pre-chemotherapy absolute neutrophil count thresholds in early-stage breast and colon cancer: A real-world retrospective study conducted in a single hospital setting in Saudi Arabia.
e12617 Background: A pre-chemotherapy absolute neutrophil count (ANC) threshold of ≥1.5 × 10⁹/L is widely used in clinical...
Survival outcomes with immune checkpoint inhibitors among patients with cancer from minoritized racial and ethnic groups: A systematic review and meta-analysis.
1648 Background: Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape across multiple malignancies...
Results from a pilot feasibility study of a novel community health worker–led intervention delivering stepped palliative care and care navigation for patients with pancreatic ductal adenocarcinoma.
12081 Background: Pancreatic Ductal Adenocarcinoma (PDAC) is associated with substantial morbidity, poor quality of life,...
Adaptive radiotherapy as a strategy for universal dosimetric accuracy across tumor sizes and locations in lung SBRT for NSCLC.
e20102 Background: Inter-fractional anatomical changes in lung SBRT raise concerns about dosimetric accuracy and potential...
Expression patterns of circulating microRNAs in classification models: New opportunities in brain tumor diagnosis.
2051 Background: Diffuse gliomas are the most common primary brain tumors and, according to the 2021 WHO classification, a...
RNDO-564-001: A first-in-human, phase 1/1b study of RNDO-564, a costimulatory bispecific antibody for the treatment of advanced bladder cancer and other Nectin-4–positive solid tumors.
TPS4640 Background: RNDO-564 is a novel CD28 x Nectin-4 bispecific antibody (bsAb) with high affinity Nectin-4 binding and...
Spatial analysis of CD8+ T cell neighbors using multiplexed immunofluorescence (MxIF) in esophageal squamous cell carcinoma (ESCC).
e16100 Background: Little is known of how the spatial orientation of the tumor immune microenvironment (TIME) contributes...
Association of secondary hematologic malignancies with radioactive iodine therapy for differentiated thyroid cancer: A systematic review and meta-analysis of retrospective cohort studies.
e18076 Background: Radioactive iodine (RAI) ablation therapy is a minimally invasive yet effective intervention for treati...
ResNets in the diagnosis of gliomas: Knowledge distillation from ResNet101 to ResNet18 for accurate and deployable WHO grade stratification.
e14093 Background: Gliomas are the most common primary malignancies of the central nervous system and remain a leading cau...
A randomized prospective trial evaluating duration of PD-1 and PD-L1 inhibitor therapy in advanced solid tumors.
2514 Background: Immune checkpoint inhibitors (IO) have revolutionized the treatment of advanced solid tumors. Despite the...
Real-world comparison of ipilimumab–nivolumab dosing strategies in melanoma brain metastases.
9558 Background: Ipilimumab 3 mg/kg plus nivolumab 1 mg/kg (Ipi3+Nivo1) is the standard immunotherapy regimen for metastat...
Target-specific therapy for actionable and approved tumor-agnostic biomarkers: Influence on survival in rare cancers.
3123 Background: Rare cancers - defined as an incidence rate of less than 6 per 100,000 diagnoses per year - collectively...
Sustaining oncology clinical trials under wartime conditions: Strategic lessons from Ukraine.
1512 Background: On February 24, 2022, when Russia launched its full-scale invasion of Ukraine, our center had already tre...